Allogene Therapeutics (ALLO) Receivables - Other (2020 - 2025)

Allogene Therapeutics has disclosed Receivables - Other across 6 years of filings, most recently posting $23.5 million for Q4 2025.

• Receivables - Other for Q4 2025 came in at $23.5 million, up 13.03% year-over-year; the trailing twelve-month figure through Dec 2025 was $23.5 million (up 13.03% YoY), and the FY2025 annual result was $23.5 million, up 13.03% from the prior year.
• Receivables - Other came in at $23.5 million for Q4 2025 at Allogene Therapeutics, roughly flat from $23.5 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $23.5 million in Q2 2025 to a low of $1.2 million in Q1 2023.
• The 5-year median for Receivables - Other is $9.8 million (2022), against an average of $12.8 million.
• Across the five-year window, Receivables - Other jumped 142.86% in 2022 and slumped 87.23% in 2023, its largest moves.
• Allogene Therapeutics' Receivables - Other stood at $4.1 million in 2021, then slumped by 63.41% to $1.5 million in 2022, then retreated by 20.0% to $1.2 million in 2023, then surged by 1631.08% to $20.8 million in 2024, then advanced by 13.03% to $23.5 million in 2025.
• The last three Receivables - Other figures came in at $23.5 million (Q4 2025), $23.5 million (Q3 2025), and $23.5 million (Q2 2025), per Business Quant data.